ROVI.MC RO

ROVI.MC LABORATORIOS FARMACEUTICOS ROVI

Healthcare · Drug Manufacturers - Specialty & Generic

7 · Fair Momentum 3.0 · Weak Safe

59.70

+2.93%

About the company

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

1.61%
26.52%
0.96
3.1B
16.49
3.62
66.98

52-week range

59.7
low 53.1 high 86.7
Yield Growth Momentum Safety Value Health

Dividend deep dive

LABORATORIOS FARMACEUTICOS ROVI (ROVI.MC), operating in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector, has a market capitalization of 3,002,475,520 EUR. The current dividend yield is 1.77%, which sits near its 5-year average of 1.64% and within its historical 5-year range of 0.66% to 2.67%. The company holds a dividend rating score of 7.0.

Dividend history

ROVI.MC has not established a consistent dividend increase streak, showing 0 consecutive years of dividend growth. The 3-year dividend CAGR is -0.72%, indicating a slight recent decline, while the 5-year dividend CAGR stands at 39.80%. Historical dividend payments (in EUR) include: 0.1612 (2014), 0.169 (2015), 0.139 (2016), 0.183 (2017), 0.1207 (2018), 0.0798 (2019), 0.1751 (2020), 0.3812 (2021), 0.9556 (2022), and 1.2938 (2023). Projected dividends for 2024 are 1.1037 EUR and for 2025 are 0.9351 EUR.

Dividend safety

The company's dividend appears covered with a payout ratio of 37.21% of earnings. The balance sheet shows low leverage, with a debt-to-equity ratio of 16.664.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.

Price history

89.0 58.5 28.1 2021 2022 2023 2024 2025 2026 2020-07 · 28.1 2020-08 · 31.4 2020-09 · 30.6 2020-10 · 40.5 2020-11 · 37.9 2020-12 · 40.6 2021-01 · 45.2 2021-02 · 46.0 2021-03 · 48.2 2021-04 · 57.0 2021-05 · 58.4 2021-06 · 59.5 2021-07 · 53.0 2021-08 · 56.5 2021-09 · 60.6 2021-10 · 64.6 2021-11 · 73.8 2021-12 · 65.4 2022-01 · 72.3 2022-02 · 67.2 2022-03 · 65.2 2022-04 · 62.4 2022-05 · 58.4 2022-06 · 51.0 2022-07 · 49.1 2022-08 · 44.2 2022-09 · 46.0 2022-10 · 36.4 2022-11 · 36.1 2022-12 · 38.8 2023-01 · 41.7 2023-02 · 38.5 2023-03 · 40.2 2023-04 · 41.3 2023-05 · 42.3 2023-06 · 43.7 2023-07 · 52.5 2023-08 · 51.4 2023-09 · 50.5 2023-10 · 56.1 2023-11 · 60.2 2023-12 · 64.0 2024-01 · 74.0 2024-02 · 80.9 2024-03 · 84.3 2024-04 · 87.8 2024-05 · 87.5 2024-06 · 89.0 2024-07 · 79.5 2024-08 · 71.6 2024-09 · 78.1 2024-10 · 64.5 2024-11 · 63.0 2024-12 · 65.5 2025-01 · 53.2 2025-02 · 51.5 2025-03 · 51.5 2025-04 · 54.5 2025-05 · 54.8 2025-06 · 54.2 2025-07 · 58.0 2025-08 · 58.1 2025-09 · 61.1 2025-10 · 59.5 2025-11 · 63.5 2025-12 · 71.9 2026-01 · 84.8 2026-02 · 80.8 2026-03 · 79.4 2026-04 · 59.3 2026-05 · 57.9 2026-06 · 53.8 2026-07 · 53.7
Price

Dividend profile

Frequency
Annual
Growth (TTM)
+2.6%
CAGR 3y
-0.7%
+39.8%
0 years

(5-year)

Now 1.6%
0.7% avg 1.6% 2.7%

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

CAGR 3y -0.7% CAGR 5y +39.8%
14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

16.7%
3.65
1.77
Debt vs cash
Debt Cash
Total debt
114.4M EUR
Total cash
97.4M EUR
183.4M EUR

Latest reported balance-sheet figures.

Appears in these lists

ROVI.MC qualifies for these curated dividend rankings.

Information, not financial advice.

Quantic · Free

Track ROVI.MC and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →